Drug intelligence / Profile preview

Antineoplaston A5

Development stage: Unknown
Lead developer: Burzynski Research Institute
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

Antineoplaston A5 is an investigational antineoplastic agent developed by the Burzynski Clinic, consisting of a mixture of peptides and amino acid derivatives. Originally derived from human urine and subsequently synthesized, it is part of a larger group of compounds termed "antineoplastons" by Dr. Stanislaw Burzynski. The agent is administered via intravenous injection and is hypothesized to function as a "biochemical corrector" that normalizes the growth of cancer cells by modulating gene expression and signal transduction. Clinical development has primarily focused on Phase 1 studies for various types of cancer, although the treatment remains highly controversial and lacks FDA approval for commercial use.

Other names: Antineoplaston A-5

Beyond the preview

Go deeper on Antineoplaston A5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antineoplaston A5.

Explore the full profile